Freenome Raises $290M in Series D

Freenome has successfully raised $290M in a Series D at a $2.7B valuation led by Perceptive Advisors, T. Rowe Price.

Company Overview

Freenome is a Biotech company headquartered in South San Francisco, CA, founded in 2014 with 500+ employees.

Early cancer detection using multiomics and machine learning

Fundraising Details

Amount Raised: $290M
Round Type: Series D
Valuation: $2.7B
Date: 2025-10-13
Investors: Perceptive Advisors, T. Rowe Price

About Freenome

Early cancer detection using multiomics and machine learning The company is positioned in the Biotech sector, serving a growing market with innovative solutions.

Key Information

Headquarters: South San Francisco, CA
Founded: 2014
Team Size: 500+
Industry: Biotech

What This Means

This funding round demonstrates strong investor confidence in Freenome's vision and execution. The capital will likely be used to:

Scale Operations: Expand the team and operational capacity
Product Development: Enhance existing products and develop new features
Market Expansion: Enter new markets and strengthen presence in existing ones
Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Freenome's successful fundraising reflects the strong fundamentals and growth potential in this space.

Valuation Milestone

Reaching a $2.7B valuation marks an important milestone for Freenome, positioning the company among notable players in the Biotech industry.

Looking Ahead

With this new capital, Freenome is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

This fundraising news was reported on 2025-10-13. For more information about Freenome, visit their headquarters at South San Francisco, CA.

Freenome